Safety and Glycemic Outcomes of the MiniMed 780G System with a Disposable All-in-One Sensor
Authors' conclusion
MM780G use with the Simplera Sync sensor is safe and demonstrated improved glycemic outcomes in both pediatric and adult participants with T1D, compared with the run-in period.
Study context
- Population
- Youths (aged 7–17 years) and adults (aged 18–80 years) with T1D, 24 sites in the United States
- Comparison
- Advanced hybrid closed-loop (AHCL) vs run-in
- Outcome
- Mean TIR, youths
- Follow-up
- Last 6-7 weeks of study vs run-in
Methodological detailsmulticentre (24 US sites)
- Multicentre (24 US sites)
Main finding
As reported in the abstract
Mean time in range (TIR) in youths increased from run-in to study end (P < 0.001), primarily due to reduced time above range
54.4% ± 15.7% to 71.4% ± 9.9%
Further findings
Mean TIR, adults · last 6-7 weeks of study vs run-in
- Mean TIR in adults increased (P < 0.001), primarily due to reduced time above range
- 66.5% ± 12.6% to 80.2% ± 8.1%
Time in automation
- Time in automation
- >93%
TIR with recommended optimal settings (ROS)
- TIR in youths using ROS
- 74.7% ± 9.3%
- TIR in adults using ROS
- 83.8% ± 7.4%
Automated share of total daily insulin dose · throughout the study
- Total daily insulin dose automated (auto basal and auto correction), both cohorts
- ∼60%
Safety
TBR <70 mg/dL · last 6-7 weeks of study vs run-in
- Slight increase in TBR in youths (P < 0.001)
- 1.6% ± 1.7% to 1.9% ± 1.4%
- No significant difference in TBR in adults
Serious adverse events
- Severe hypoglycemia
- 2 cases
- DKA (not related to the device)
- 1 episode
Original publication
Safety and Glycemic Outcomes of the MiniMed 780G System with a Disposable All-in-One Sensor. Diabetes Technol Ther. Published 18 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →